Replies to post #5096 on Dendreon Corp fka DNDNQ

[walldiver]

Yes, if Provenge works, the potential longer survival time of the early enrollees should have some sort of an offsetting effect. There were 179 patients enrolled as of 2/6/06. Nothing has been released about the enrollment rate before that date, although Nicole Provost presented data from 99 patients at the CTGTAC in February or March of 2006. I would estimate that there were about that many enrolled as of Feb 2005, meaning that approx 20% of the patients in the trial will have been enrolled for 45 to 65 months if the interim look happens in Nov 2008.